Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Dementia01:30

Dementia

526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
526
Amyloid Fibrils03:03

Amyloid Fibrils

11.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations.

The Journal of experimental medicine·2024
Same author

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.

Annals of neurology·2024
Same author

Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies.

Experimental & molecular medicine·2024
Same author

APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread.

Cell·2023
Same author

Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.

Neuron·2023
Same author

Current status of amyloid-targeting immunotherapies for Alzheimer's disease.

Science translational medicine·2023

Video Experimental Relacionado

Updated: Jan 18, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.4K

Enfermedad de Alzheimer: una actualización sobre la patobiología y las estrategias de tratamiento

Justin M Long1, David M Holtzman1

  • 1Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

Cell
|October 1, 2019
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Alzheimer (EA) implica una patobiología compleja más allá de las placas amiloides y los ovillos de tau. La investigación destaca nuevos procesos celulares, pero aún se necesitan tratamientos efectivos para la enfermedad de Alzheimer.

Más Videos Relacionados

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.7K

Videos de Experimentos Relacionados

Last Updated: Jan 18, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.4K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.7K

Área de la Ciencia:

  • Neurología
  • La neurociencia
  • Patología

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) se caracteriza por placas amiloides y ovillos neurofibrilares.
  • Descubrimientos recientes revelan otros procesos celulares y moleculares críticos involucrados en la patobiología de la EA.
  • Los tratamientos actuales para la EA no modifican la enfermedad y los ensayos clínicos han tenido un éxito limitado.

Objetivo del estudio:

  • Revisar los avances recientes en la comprensión de la patobiología de la enfermedad de Alzheimer.
  • Para discutir las estrategias actuales de tratamiento de la enfermedad de Alzheimer y los ensayos clínicos.
  • Identificar oportunidades para desarrollar futuras terapias modificadoras de la enfermedad de Alzheimer.

Principales métodos:

  • Revisión de la literatura de recientes descubrimientos fundamentales en la patobiología de la enfermedad de Alzheimer.
  • Análisis de las estrategias de tratamiento actuales y los resultados de los ensayos clínicos de fase 3.
  • Exploración de investigaciones emergentes para nuevos objetivos terapéuticos.

Principales resultados:

  • La patobiología de la enfermedad de Alzheimer es más compleja de lo que se entendía anteriormente, e involucra múltiples vías celulares y moleculares.
  • A pesar de las extensas investigaciones, actualmente no se dispone de tratamientos definitivos para la enfermedad de Alzheimer.
  • Numerosos ensayos clínicos no han demostrado beneficios significativos, lo que subraya la necesidad de nuevos enfoques.

Conclusiones:

  • Una comprensión completa de la compleja patobiología de la EA es crucial para desarrollar tratamientos efectivos.
  • Las futuras estrategias terapéuticas para la enfermedad de Alzheimer deben considerar una gama más amplia de mecanismos patológicos.
  • La investigación continua sobre nuevos objetivos y enfoques es esencial para avanzar en el tratamiento de la EA.